Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

被引：1
|
作者：
Sher, Amna Falak [1 ]
Bruce, Justine Yang [2 ]
Gabrail, Nashat Y. [3 ]
Anderson, Ian Churchill [4 ]
Patrikidou, Anna [5 ]
Sanborn, Rachel E. [6 ]
Cho, Jae Yong [7 ]
Lee, Arielle Shebay [8 ]
Lee, Jong-Seok [9 ]
Nott, Louise M. [10 ]
Oh, Do-Youn [11 ]
Oh, Sang Cheul [12 ]
Oh, Sung Yong [13 ]
Wang Yinghui [14 ]
Wang Zejing [14 ]
Guthrie, Troy H. [15 ]
机构：
[1] Stony Brook Univ Hosp, Stony Brook, NY USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Gabrail Canc Ctr Res LLC, Canton, OH USA
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Sarah Cannon Res Inst, London, England
[6] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
[7] Yonsei Univ, Gangnam Severance Hosp, Seoul, South Korea
[8] UT Hlth, HOPE Canc Ctr East Texas, Tyler, TX USA
[9] Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea
[10] Royal Hobart Hosp, Hobart, Tas, Australia
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Korea Univ, Guro Hosp, Seoul, South Korea
[13] Dong A Univ Hosp, Busan, South Korea
[14] Seattle Genet Inc, Bothell, WA USA
[15] 21st Century Oncol, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS185
引用
收藏
页数：2
相关论文
共 50 条
  • [41] 177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
    Hofman, Michael
    Emmett, Louise
    Iravani, Amir
    Sandhu, Shahneen
    Joshua, Anthony
    Pattison, David
    Goh, Jeffrey
    Kirkwood, Ian
    Tan, Thean Hsiang
    Francis, Roslyn
    Ng, Siobhan
    Rutherford, Natalie
    Gedye, Craig
    Scott, Andrew
    Lee, Sze-Ting
    Weickhardt, Andrew
    Ramdave, Shakher
    Kwan, Edmond
    Azad, Arun
    Macdonald, William
    Redfern, Andrew
    Zhang, Alison
    Stockler, Martin
    Martin, Andrew
    Davis, Ian
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [42] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
    Meisel, Jane Lowe
    Pluard, Timothy J.
    Vinayak, Shaveta
    Stringer-Reasor, Erica Michelle
    Brown-Glaberman, Ursa
    Dillon, Patrick Michael
    Basho, Reva K.
    Varadarajan, Ramya
    O'Shaughnessy, Joyce
    Han, Hyo S.
    Sinha, Rajni
    Fox, Jenny R.
    Villanueva, Rafael
    Chen, Lin Chi
    Wu, Sheng
    Li, Hong
    Tran, Sinhan
    Manso, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Nakabayashi, Mari
    Werner, Lilian
    Courtney, Kevin D.
    Buckle, Geoffrey
    Oh, William K.
    Bubley, Glen J.
    Hayes, Julia H.
    Weckstein, Douglas
    Elfiky, Aymen
    Sims, Danny M.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    BJU INTERNATIONAL, 2012, 110 (11) : 1729 - 1735
  • [44] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [45] Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
    Attard, Gerhardt
    Merseburger, Axel S.
    Arlt, Wiebke
    Sternberg, Cora N.
    Feyerabend, Susan
    Berruti, Alfredo
    Joniau, Steven
    Geczi, Lajos
    Lefresne, Florence
    Lahaye, Marjolein
    Shelby, Florence Nave
    Pissart, Genevieve
    Chua, Sue
    Jones, Robert J.
    Tombal, Bertrand
    JAMA ONCOLOGY, 2019, 5 (08) : 1159 - 1167
  • [46] A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Pook, David William
    Geynisman, Daniel M.
    Carles, Joan
    De Braud, Filippo G.
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal A.
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia
    Harris, Adam
    Huang, Kuan-Chieh
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
    Teply, Benjamin A.
    Wang, Hao
    Luber, Brandon
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Spitz, Avery
    DeCarli, Morgan
    Sinibaldi, Victoria
    Pratz, Caroline F.
    Lu, Changxue
    Silberstein, John L.
    Luo, Jun
    Schweizer, Michael T.
    Drake, Charles G.
    Carducci, Michael A.
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    LANCET ONCOLOGY, 2018, 19 (01): : 76 - 86
  • [48] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [49] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [50] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    LANCET, 2010, 376 (9747): : 1147 - 1154
12345